Physician profile
Nathan D Livers
NPI 1356509236
$5,181.06
in general payments reported to CMS, 2019-2025
34 companies · $1,502 in 2025
The $1,502 reported for 2025 was more than what 93% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $413 · 2020: $265 · 2021: $580 · 2022: $556 · 2023: $1,498 · 2024: $367 · 2025: $1,502.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,978 · Travel and Lodging: $1,304 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,977.83 |
| Travel and Lodging | $1,303.84 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $1,435.22 | 2019-2025 | |
| Modernatx, INC. | $1,224.99 | 2023 | |
| Abbvie INC. | $561.56 | 2019-2023 | |
| Astellas Pharma US INC | $482.02 | 2022-2025 | Veozah |
| Caldera Medical, INC | $194.61 | 2023-2024 | Desara |
| Coopersurgical, INC. | $120.79 | 2019 | |
| Allergan, INC. | $117.14 | 2019-2021 | |
| Gynesonics, INC. | $96.07 | 2021 | |
| Avion Pharmaceuticals | $86.60 | 2019-2021 | |
| Rhythm Pharmaceuticals, INC. | $75.97 | 2021 | |
| Organon LLC | $71.63 | 2021-2024 | |
| Pfizer INC. | $65.50 | 2022-2024 | |
| Davol INC. | $57.64 | 2022 | |
| Exeltis, USA INC. | $56.70 | 2020-2023 | Slynd |
| Merck Sharp & Dohme LLC | $56.32 | 2020-2023 | Gardasil 9 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $51.94 | 2023-2025 | |
| Biogen, INC. | $44.56 | 2025 | Zurzuvae |
| Therapeuticsmd, INC. | $43.56 | 2021-2022 | |
| Hologic Sales and Service, LLC | $40.15 | 2019-2025 | Aptima, Thinprep 2000 Processor |
| Mylan Pharmaceuticals INC. | $39.73 | 2019-2022 | |
| Ethicon US, LLC | $38.28 | 2021 | |
| Shield Therapeutics INC | $33.96 | 2023-2025 | Accrufer |
| Millicent US INC | $26.17 | 2025 | Intrarosa |
| Scynexis, INC. | $25.57 | 2022 | |
| Amag Pharmaceuticals, INC. | $21.90 | 2019-2020 | |
| Becton, Dickinson and Company | $20.04 | 2019 | |
| Meditrina | $16.09 | 2021 | |
| Smith+Nephew, INC. | $14.44 | 2022 | |
| Evofem Biosciences, INC. | $13.43 | 2021 | |
| Lupin INC. | $13.12 | 2020 | |
| Minerva Surgical, INC | $12.91 | 2019 | |
| Covidien LP | $11.24 | 2019 | |
| Myovant Sciences INC. | $11.21 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Livers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.